公开(公告)号：US20230167080A1

公开(公告)日：2023-06-01

申请号：US18060027

申请日：2022-11-30

Applicant: Pfizer Inc.

Inventor： Leanne Marie BUZON ,  Kimberly O'Keefe CAMERON ,  Kevin Francis DEBOYACE ,  Kevin James FILIPSKI ,  David Andrew GRIFFITH ,  Bethany Lyn KORMOS ,  Shenping LIU ,  Luis Angel MARTINEZ ALSINA ,  Matthew Richard REESE ,  Rachel Jane ROTH FLACH ,  Yuan ZHANG

IPC: C07D333/68 ,  A61P3/04 ,  A61P9/00

CPC classification number: C07D333/68 ,  A61P3/04 ,  A61P9/00 ,  C07B2200/13

Abstract: Described herein are compounds of Formula I,




wherein the variables are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, diabetes, kidney disease, NASH and heart failure.

公开(公告)号：US20210355117A1

公开(公告)日：2021-11-18

申请号：US16492558

申请日：2018-03-06

Applicant: Pfizer Inc.

Inventor： Michael Aaron BRODNEY ,  Thomas Allen CHAPPIE ,  Jinshan Michael CHEN ,  Jotham Wadsworth COE ,  Karen Jean COFFMAN ,  Paul GALATSIS ,  Michelle Renee GARNSEY ,  Christopher John HELAL ,  Jaclyn Louise Henderson ,  Bethany Lyn KORMOS ,  Ravi G. KURUMBAIL ,  Luis Angel MARTINEZ-ALSINA ,  Martin Youngjin PETTERSSON ,  Matthew Richard REESE ,  Colin Richard ROSE ,  Antonia Friederike STEPAN ,  Patrick Robert VERHOEST ,  Travis T. WAGER ,  Joseph Scott WARMUS ,  Yuan ZHANG

IPC: C07D471/04

Abstract: The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.